Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
SK Biopharmaceutical is eyeing a share of the 4 trillion won US antiepileptic drug market with its cenobamate tablet Xcopri, which treats partial-onset seizures in adults.
The drug, approved by the US Food and Drug Administration (FDA) on November 21 last year, provides an extra needed treatment option for people with seizures.
Xcopri is the first Korean novel drug, researched and developed entirely and independently by a Korean pharma firm, notes SK Biopharmaceutical CEO Cho.
It is a product of Cho's 15-year research and development drive.
According to the US FDA, the safety and efficacy of XCOPRI were established in two studies that enrolled 655 adults, which were randomized, double-blind, and placebo-controlled.
The FDA granted Xcopri's approval to SK Life Science Inc., the US arm of SK Biopharmaceutical.
Thus, SK Life Science will undertake the US distribution of Xcopri.
